Organisation paid for research Program year 2025 Source: CMS Open Payments

Apex Research Institute

Neither a doctor nor a teaching hospital

Research payments

$797,000

75 payments

Through program year 2025, Apex Research Institute is reported as receiving $797,000 in research payments, across 75 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $155,822 13
2024 Research $115,527 22
2023 Research $65,647 13
2022 Research $15,700 2
2021 Research $381,836 14
2020 Research $23,604 9
2019 Research $38,864 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $403,201 18 payments
  2. E.R. Squibb & Sons, L.L.C. $214,795 3 payments
  3. Novo Nordisk AS $168,901 51 payments
  4. Biogen, Inc. $9,000 1 payment
  5. Novartis Pharmaceuticals Corporation $1,103 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Ly3819253 and Ly3832479 in Participants With Mild to Moderate Covid-19 Illness $277,696 4 payments
  2. Nn6535-4725 $140,881 50 payments
  3. A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) $133,524 2 payments
  4. Phase 2 PoC in Early AD Patients - A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer s Disease (TargetT $81,271 1 payment
  5. A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate Covid-19 Illness (Blaze-4) $71,849 4 payments
  6. Anti-Amyloid Treatment in Asymptomatic Alzheimers Disease -A4 Study $39,381 3 payments
  7. Nn6535-4730 $28,020 1 payment
  8. A Phase 2, randomized, multicenter, two-arm, open-label study to compare the pharmacodynamics, safety, and tolerability of subcutaneous versus intravenous administration of Aducanumab (BIIB037) in participants with Alzheimer's disease $9,000 1 payment
  9. A Randomized, Double Blind, Placebo Controlled, Parallel Group Phase 3 Study of Baricitinib in Patients With Covid 19 Infection $6,648 1 payment
  10. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $5,942 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record